Apr 01, 2019 7:30am EDT Emerald Bioscience, Inc. Announces DEA Decision that its Proprietary Cannabidiol Analog is not a Regulated Chemical or Controlled Substance Under Controlled Substances Act
Mar 25, 2019 8:00am EDT Nemus Bioscience, Inc. Changes Name to Emerald Bioscience, Inc. and Provides Update of Recent Research Accomplishments
Mar 18, 2019 7:30am EDT Nemus Bioscience Reports Nanoemulsion of NB1111 Superior to First-Line Therapy, Latanoprost, in Lowering Intraocular Pressure in Validated Normotensive Animal Model Testing
Mar 12, 2019 7:30am EDT Nemus Bioscience Confirms NB1111 Mechanism of Action and Reports Positive Results from Glaucoma Biomarker Studies in Human Donor Tissues
Mar 04, 2019 7:30am EST Nemus Bioscience Signs Agreement with Noramco to Manufacture Proprietary Cannabidiol Analog
Feb 14, 2019 7:00am EST Nemus Bioscience Signs Agreement with Pharmaceuticals International Inc. to Develop Dosage Formulation for Human Dosing with NB1111 for Glaucoma
Jan 23, 2019 7:30am EST Nemus Bioscience to Present at the NobleCon XV and 8th Annual Glaucoma 360 New Horizons Forum
Jan 03, 2019 7:00am EST Nemus Bioscience to Present at the 2nd Annual Sach’s Neuroscience Innovation Forum and Biotech Showcase 2019
